Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“Even decades after treatment, multiple myeloma (MM) survivors tire more easily than people with no history of the disease, according to new research.”
Conventional cancer treatement for the newly diagnosed multiple myeloma (MM) patient is a conundrum. Do I undergo chemotherapy and radiation in hopes of killing my MM? If I do undergo MM therapies however, I will give myself short, long-term and late stage side effects including accelerated aging?
So what does the newly diagnosed multiple myeloma (MM) patient do?!?
First and foremost, a diagnosis of multiple myeloma does not have to mean aggressive, high-dose chemotherapy and radiation.
Surgery, as an example, can de-bulk a tumor simply by cutting it out of your body. When I was first diagnosed, I had a single plasmacytoma that was surgically removed.
But when you MM has spread or is “systemic,” what do you do?
Yes, there are multiple myeloma cases that call for aggressive chemotherapy. In the case of my type of cancer, multiple myeloma, a diagnosis at a later stage or considerable bone involvement certainly calls for aggressive chemo in an attempt to put the MM patient into remission.
At the same time however, a diagnosis of early stage multple myeloma may not require aggressive MM chemotherapy. Meaning, the patient, depending on his/her stage, age, health status, etc. may live a higher quality of life and a longer overall survival by pursuing a “less is more” approach to chemotherapy.
Aggressive or high-dose multiple myeloma chemotherapy often leads to serious long-term and late stage side effects.
“Even decades after treatment, cancer survivors tire more easily than people with no history of the disease, according to new research.
The findings hint at a pattern of “accelerated aging” for people with a cancer history.
“The main goal of cancer treatment has been survival, but studies like this suggest that we need also to examine the longer-term effects on health and quality of life,” said the study’s senior author, Jennifer Schrack. She’s an assistant professor at the Johns Hopkins School of Public Health.
The researchers analyzed data from a long-term study on normal aging. More than 300 were cancer survivors, with an average age of 74. About 1,330 of those studied, average age 69, had not had the disease.
Participants completed periodic treadmill tests and 400-meter walks (two-tenths of a mile) to assess their endurance, beginning in 2007. Afterward, they were asked to rate their level of fatigue.
The researchers compared results of cancer survivors with the results of adults who never had cancer.
“We were surprised by the magnitude of the differences we found,” Schrack said in a university news release.
On average, those with a history of cancer treatment tired more easily on the treadmill tests and took longer to finish the walking tests, the study found.
It showed cancer treatment was linked to a 1.6 times greater risk of a high level of fatigue.
Being older than 65 was associated with a 5.7 higher risk for this decline in endurance.
The cancer survivors walked, on average, 14 seconds slower and got tired more quickly, the study found.
The results were published recently in the journal Cancer. The U.S. National Cancer Institute and the U.S. National Institute on Aging funded the research.
As of 2016, there were some 16 million cancer survivors in the United States alone, the study’s authors noted.
Previous studies have shown that cancer treatment — often including chemotherapy and radiation — appears to speed up the aging process, leading to fatigue, a decline in brain function, heart disease and return of cancer.
These new findings “support the idea that a history of cancer is associated with higher fatigability and that this effect worsens with advancing age,” Schrack said.
“The long-term goal is that doctors and patients will be able to take those specific long-term effects into account when they decide how to treat different cancers,” she added.
“New research indicates that certain anti-cancer therapies may hasten cellular aging, where changes in the DNA of patients may contribute to greater inflammation and fatigue…
Gene activity is often adjusted during life through epigenetic changes, or physical modifications to DNA that do not involve altering the underlying DNA sequence. Some individuals may experience epigenetic age acceleration (EAA) that puts them at a higher risk of age-related conditions than other individuals of the same chronological age.
Investigators recently examined EAA changes during and following cancer treatment, and they looked for a potential link between these changes and fatigue in patients with head and neck cancer (HNC).
Our findings add to the body of evidence suggesting that long-term toxicity and possibly increased mortality incurred from anti-cancer treatments for patients with HNC may be related to increased EAA and its association with inflammation,..”
The authors noted that interventions to reduce inflammation, including prior to cancer treatment, might benefit patients by decelerating the aging process and subsequently reducing age-related chronic health problems such as fatigue.
An accompanying editorial stresses that chronic fatigue in patients receiving treatment for cancer is not just a symptom; it may also play an important role in influencing patients’ health.”
[…] Myeloma Chemo = Accelerated Aging […]Reply